Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial - 01/09/16
, Armando Santoro, ProfMD b, Margaret Shipp, ProfMD c, Pier Luigi Zinzani, ProfMD d, John M Timmerman, MD e, Stephen Ansell, ProfMD f, Philippe Armand, MD c, Michelle Fanale, MD g, Voravit Ratanatharathorn, MD h, John Kuruvilla, MD i, Jonathon B Cohen, MD j, Graham Collins, MD k, Kerry J Savage, MD l, Marek Trneny, ProfMD m, Kazunobu Kato, MD n, Benedetto Farsaci, MD n, Susan M Parker, PhD n, Scott Rodig, MD o, Margaretha G M Roemer, MS c, Azra H Ligon, PhD o, Andreas Engert, ProfMD pSummary |
Background |
Malignant cells of classical Hodgkin’s lymphoma are characterised by genetic alterations at the 9p24.1 locus, leading to overexpression of PD-1 ligands and evasion of immune surveillance. In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients with relapsed and refractory classical Hodgkin’s lymphoma, with an acceptable safety profile. We aimed to assess the clinical benefit and safety of nivolumab monotherapy in patients with classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin.
Methods |
In this ongoing, single-arm phase 2 study, adult patients (aged ≥18 years) with recurrent classical Hodgkin’s lymphoma who had failed to respond to autologous stem-cell transplantation and had either relapsed after or failed to respond to brentuximab vedotin, and with an Eastern Cooperative Oncology Group performance status score of 0 or 1, were enrolled from 34 hospitals and academic centres across Europe and North America. Patients were given nivolumab intravenously over 60 min at 3 mg/kg every 2 weeks until progression, death, unacceptable toxicity, or withdrawal from study. The primary endpoint was objective response following a prespecified minimum follow-up period of 6 months, assessed by an independent radiological review committee (IRRC). All patients who received at least one dose of nivolumab were included in the primary and safety analyses. This trial is registered with ClinicalTrials.gov, number NCT02181738.
Findings |
Among 80 treated patients recruited between Aug 26, 2014, and Feb 20, 2015, the median number of previous therapies was four (IQR 4–7). At a median follow-up of 8·9 months (IQR 7·8–9·9), 53 (66·3%, 95% CI 54·8–76·4) of 80 patients achieved an IRRC-assessed objective response. The most common drug-related adverse events (those that occurred in ≥15% of patients) included fatigue (20 [25%] patients), infusion-related reaction (16 [20%]), and rash (13 [16%]). The most common drug-related grade 3 or 4 adverse events were neutropenia (four [5%] patients) and increased lipase concentrations (four [5%]). The most common serious adverse event (any grade) was pyrexia (three [4%] patients). Three patients died during the study; none of these deaths were judged to be treatment related.
Interpretation |
Nivolumab resulted in frequent responses with an acceptable safety profile in patients with classical Hodgkin’s lymphoma who progressed after autologous stem-cell transplantation and brentuximab vedotin. Therefore, nivolumab might be a new treatment option for a patient population with a high unmet need. Ongoing follow-up will help to assess the durability of response.
Funding |
Bristol-Myers Squibb.
Le texte complet de cet article est disponible en PDF.Plan
Vol 17 - N° 9
P. 1283-1294 - septembre 2016 Retour au numéro
Article précédent
- Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
- Marcia S Brose, Maria E Cabanillas, Ezra E W Cohen, Lori J Wirth, Todd Riehl, Huibin Yue, Steven I Sherman, Eric J Sherman
- Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study
- Anita Villani, Ari Shore, Jonathan D Wasserman, Derek Stephens, Raymond H Kim, Harriet Druker, Bailey Gallinger, Anne Naumer, Wendy Kohlmann, Ana Novokmet, Uri Tabori, Marta Tijerin, Mary-Louise C Greer, Jonathan L Finlay, Joshua D Schiffman, David Malkin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?